ALK and non-small cell lung carcinoma: Second, not all clinical trials estimated median DOR or median OS for several therapies including dacomitinib for EGFR‐mutated NSCLC, alectinib for ALK‐mutated NSCLC, and larotrectinib for NTRK‐mutated NSCLC.